Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.
Tan WS, O'Donnell M, Li R, Kamat AM, Packiam VT. Tan WS, et al. Among authors: kamat am. Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00225-0. doi: 10.1016/j.euo.2023.10.009. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492318 No abstract available.
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study.
Basin MF, Miguel CM, Jacob JM, Goldberg H, Grivas P, Spiess PE, Necchi A, Kamat AM, Pavlick DC, Huang RSP, Lin DI, Danziger N, Sokol ES, Sivakumar S, Graf R, Cheng L, Vasan N, Ross J, Basnet A, Bratslavsky G. Basin MF, et al. Among authors: kamat am. Target Oncol. 2024 Oct 5. doi: 10.1007/s11523-024-01100-w. Online ahead of print. Target Oncol. 2024. PMID: 39369133
FGFR Inhibition in Urothelial Carcinoma.
Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. Li R, et al. Among authors: kamat am. Eur Urol. 2024 Sep 30:S0302-2838(24)02605-8. doi: 10.1016/j.eururo.2024.09.012. Online ahead of print. Eur Urol. 2024. PMID: 39353825 Review.
Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG).
Contieri R, Soloway MS, Gontero P, Herr H, Kassouf W, Mertens LS, Moschini M, O'Donnell M, Palou J, Psutka SP, Rouprêt M, Teoh JYC, Kamat AM. Contieri R, et al. Among authors: kamat am. Eur Urol Oncol. 2024 Aug 31:S2588-9311(24)00186-X. doi: 10.1016/j.euo.2024.08.001. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39218742 Review.
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.
Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. Campbell MT, et al. Among authors: kamat am. Cancer Res Commun. 2024 Sep 1;4(9):2444-2453. doi: 10.1158/2767-9764.CRC-24-0237. Cancer Res Commun. 2024. PMID: 39207194 Free PMC article.
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, Tan WS, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y. Taylor JI, et al. Among authors: kamat am. BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509. Online ahead of print. BJU Int. 2024. PMID: 39183466
494 results